Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares dropped 4.5% during mid-day trading on Wednesday . The stock traded as low as $10.95 and last traded at $10.97. Approximately 1,672,818 shares changed hands during trading, an increase of 395% from the average daily volume of 337,931 shares. The stock had previously closed at $11.49.
Silverback Therapeutics Trading Down 4.5%
The company’s 50-day moving average is $9.66 and its 200 day moving average is $12.27. The stock has a market capitalization of $395.56 million, a PE ratio of -4.53 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- You Still Think Silver’s a Joke? Watch What Happens Next.
- A U.S. “birthright” claim worth trillions – activated quietly
- A month before the crash
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- YDES Could Be 2026’s Biotech Breakthrough
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
